Inflammation and Prostatic Diseases: From Bench to Bedside
From a Satellite Symposium to the 30th European Association of Urology Annual Congress, 20-24 March 2015, Madrid, Spain
Contents, European Urology Supplements Volume 14, Issue 9
Javier BurgosUrology Department, Ramon y Cajal Hospital, Alcala University, Madrid, Spain
Jack A. SchalkenIncreasing insight into benign prostatic hyperplasia (BPH) pathogenesis indicates that restoring tissue endocrine metabolism and reducing chronic inflammation are prostate specific targets for treatment of BPH.
J. Curtis NickelAn increased understanding of the role of prostatic inflammation in the pathogenesis, symptomatology, and progression of benign prostatic hyperplasia (BPH) is likely to change the treatment paradigm for BPH.
Francesco ScaglioneStandardisation of herbal medicines is essential to ensure a consistent level of clinical activity and safety. In the case of Serenoa repens , the n-hexane lipidosterolic extract is the only formulation currently considered by the European Medicines Agency to be a “well-established medical use product”.
Comparison of the Effects of Hexanic Extract of Serenoa repens (Permixon) and Tamsulosin on Inflammatory Biomarkers in the Treatment of Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms
Grégoire Y. RobertDownregulation of inflammation-related genes and proteins by Serenoa repens (Permixon) was associated with meaningful symptomatic improvement in patients with moderate to severe lower urinary tract symptoms. Patients with high chronic prostatic inflammation may benefit from early treatment with Permixon.